Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
Bausch Health (NYSE:BHC) has expanded its Board of Directors from ten to twelve members with the appointment of two seasoned pharmaceutical industry executives, effective July 22, 2025. Michael Goettler, former CEO of Viatris, will serve on the Talent and Compensation Committee and Science and Technology Committee. Sandra Leung, former Executive VP and General Counsel of Bristol Myers Squibb, will join the Nominating and Corporate Governance Committee.
Board Chairman John A. Paulson expressed confidence that their extensive industry experience and leadership capabilities will provide strategic guidance for the company's continued evolution and strengthen its commitment to stakeholders.
Bausch Health (NYSE:BHC) ha ampliato il proprio Consiglio di Amministrazione da dieci a dodici membri con la nomina di due esperti dirigenti del settore farmaceutico, a partire dal 22 luglio 2025. Michael Goettler, ex CEO di Viatris, entrer脿 a far parte del Comitato per il Talento e la Retribuzione e del Comitato per la Scienza e la Tecnologia. Sandra Leung, ex Vicepresidente Esecutiva e Consigliere Generale di Bristol Myers Squibb, si unir脿 al Comitato per la Nomina e la Governance Aziendale.
Il Presidente del Consiglio, John A. Paulson, ha espresso fiducia che la loro vasta esperienza nel settore e le capacit脿 di leadership offriranno una guida strategica per l'evoluzione continua dell'azienda e rafforzeranno l'impegno verso gli stakeholder.
Bausch Health (NYSE:BHC) ha ampliado su Junta Directiva de diez a doce miembros con el nombramiento de dos ejecutivos experimentados de la industria farmac茅utica, efectivo a partir del 22 de julio de 2025. Michael Goettler, ex CEO de Viatris, formar谩 parte del Comit茅 de Talento y Compensaci贸n y del Comit茅 de Ciencia y Tecnolog铆a. Sandra Leung, ex Vicepresidenta Ejecutiva y Asesora General de Bristol Myers Squibb, se unir谩 al Comit茅 de Nominaciones y Gobernanza Corporativa.
El Presidente de la Junta, John A. Paulson, expres贸 confianza en que su amplia experiencia en la industria y sus habilidades de liderazgo brindar谩n una gu铆a estrat茅gica para la evoluci贸n continua de la compa帽铆a y fortalecer谩n su compromiso con los interesados.
Bausch Health (NYSE:BHC)電� 2025雲� 7鞗� 22鞚茧秬搿� 鞝滌暯 鞐呹硠鞚� 瓴巾棙鞚� 頀嶋秬頃� 鞛勳洂 霊� 氇呾潉 鞛勲獏頃橃棳 鞚挫偓須岆ゼ 10氇呾棎靹� 12氇呾溂搿� 頇曤寑頄堨姷雼堧嫟. Michael Goettler 鞝� Viatris CEO電� 鞚胳灛 氚� 氤挫儊 鞙勳洂須岇檧 瓿柬暀旮办垹 鞙勳洂須岇棎靹� 頇滊彊頃� 鞓堨爼鞛呺媹雼�. Sandra Leung 鞝� Bristol Myers Squibb 攵�靷灔 瓴� 氩曤 瓿犽鞚� 歆�氇� 氚� 旮办梾 瓯半矂雱岇姢 鞙勳洂須岇棎 頃╇頃╇媹雼�.
鞚挫偓須� 鞚橃灔 John A. Paulson鞚� 鞚措摛鞚� 頀嶋秬頃� 鞐呹硠 瓴巾棙瓿� 毽崝鞁� 鞐焿鞚� 須岇偓鞚� 歆�靻嶌爜鞚� 氚滌爠鞐� 鞝勲灥鞝� 歆�旃潉 鞝滉车頃橁碃 鞚错暣甏�瓿勳瀽鞐� 雽�頃� 項岇嫚鞚� 臧曧檾頃� 瓴冹澊霛茧┌ 鞁犽毳� 響滊獏頄堨姷雼堧嫟.
Bausch Health (NYSE:BHC) a 茅largi son conseil d'administration, passant de dix 脿 douze membres, avec la nomination de deux cadres exp茅riment茅s de l'industrie pharmaceutique, effective 脿 partir du 22 juillet 2025. Michael Goettler, ancien PDG de Viatris, si茅gera au comit茅 des talents et de la r茅mun茅ration ainsi qu'au comit茅 des sciences et technologies. Sandra Leung, ancienne vice-pr茅sidente ex茅cutive et conseill猫re juridique g茅n茅rale de Bristol Myers Squibb, rejoindra le comit茅 de nomination et de gouvernance d'entreprise.
Le pr茅sident du conseil, John A. Paulson, a exprim茅 sa confiance quant au fait que leur vaste exp茅rience dans l'industrie et leurs capacit茅s de leadership offriront une orientation strat茅gique pour l'茅volution continue de l'entreprise et renforceront son engagement envers les parties prenantes.
Bausch Health (NYSE:BHC) hat seinen Vorstand von zehn auf zw枚lf Mitglieder erweitert, indem zwei erfahrene F眉hrungskr盲fte aus der Pharmaindustrie mit Wirkung zum 22. Juli 2025 berufen wurden. Michael Goettler, ehemaliger CEO von Viatris, wird im Talent- und Verg眉tungsausschuss sowie im Wissenschafts- und Technologieausschuss t盲tig sein. Sandra Leung, ehemalige Executive VP und General Counsel von Bristol Myers Squibb, wird dem Nominierungs- und Corporate-Governance-Ausschuss beitreten.
Der Vorstandsvorsitzende John A. Paulson 盲u脽erte Vertrauen darin, dass deren umfangreiche Branchenerfahrung und F眉hrungskompetenzen strategische Impulse f眉r die weitere Entwicklung des Unternehmens geben und das Engagement gegen眉ber den Stakeholdern st盲rken werden.
- None.
- None.
LAVAL, QC / / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sandra Leung to its Board of Directors, effective July 22, 2025. The appointments increase the size of the Board from ten to twelve members.
Michael Goettler is an accomplished executive with extensive leadership experience in the pharmaceutical industry. Most recently, he served as Chief Executive Officer of Viatris, where he guided the company through transformation and renewed focus. He is recognized for his expertise in steering multinational corporations and advancing healthcare solutions worldwide. Mr. Goettler will serve on the Talent and Compensation Committee and Science and Technology Committee.
Sandra Leung brings decades of experience and insight from her distinguished career in the pharmaceutical industry, most recently as Executive Vice President and General Counsel of Bristol Myers Squibb Company. Ms. Leung has provided strategic legal counsel at the highest levels, helping to guide corporate governance, compliance, and regulatory initiatives. Ms. Leung will serve on the Nominating and Corporate Governance Committee.
"On behalf of our Board, I am delighted to welcome Michael and Sandra to the Bausch Health Board. Their deep industry knowledge and leadership experience will provide invaluable guidance as the organization continues to evolve and strengthen," said John A. Paulson, Chairperson of the Bausch Health Board. "We are confident that their insights will help accelerate the strategy and reinforce the Company's commitment to patients, customers, and shareholders."
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit and connect with us on
Forward-looking Statements
This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Investor Contact:
Garen Sarafian
[email protected]
(877) 281-6642 (toll free)
Media Contact:
Katie Savastano
(908) 569-3692
SOURCE: Bausch Health Companies Inc.
View the original on ACCESS Newswire
FAQ
Who are the new Board members appointed to Bausch Health (BHC)?
What committees will the new Bausch Health (BHC) Board members serve on?
How many members are now on Bausch Health's (BHC) Board of Directors?
What experience do the new Bausch Health (BHC) Board members bring?
